Pharmafile Logo

Chronic heart failure

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

Merck ends its COVID-19 vaccine programme after disappointing early trial results

Immune responses were inferior to levels observed in recovered COVID-19 patients

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

Bayer symbol

Bayer’s finerenone scores FDA priority review for chronic kidney disease

FDA priority review is based on data from the phase 3 FIDELIO-DKD trial

- PMLiVE

CureVac and Bayer partner on mRNA-based COVID-19 vaccine

German pharma giant will support further development of CVnCoV

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links